Newsletter Subscribe
Enter your email address below and subscribe to our newsletter
Treatment
Share your love
EyePoint receives second consecutive positive recommendation from DSMC | Ophthalmology Times
(Image credit: ©peopleimages.com/AdobeStock) The Data Safety Monitoring Committee (DSMC) recently completed its second scheduled review of EyePoint Pharmaceuticals’ ongoing phase 3 trial evaluating DURAVYU for the treatment of wet AMD (wAMD), EyePoint announced.1 The DSMC concluded that both the LUGANO…
Limitations of Current Dry Eye Therapies | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Treatment Selection in Dry Eye Disease | Ophthalmology Times
The Viewpoints series “Reimagining Dry Eye Management: Targeting Tear Function for Sustained Relief” convenes leading experts in ophthalmology and optometry to discuss evolving perspectives on dry eye disease (DED). Under the moderation of Kendall Donaldson, MD, MS, the panel—comprising Cecelia…
Coave Therapeutics reveals lead gene therapy program, CoTx-101 | Ophthalmology Times
(Image Credit: AdobeStock) Coave Therapeutics has announced its lead gene therapy program, CoTx-101, for the treatment of retinal vascular diseases, such as wet age-related macular degeneration (wAMD) and diabetic macular edema (DME). The company describes CoTx-101 as the combination of…
Brain Stimulation Boosts Vision Recovery After Stroke
A new study from researchers at EPFL introduces a promising non-invasive brain stimulation technique aimed at restoring visual function in stroke patients with hemianopia. The treatment combines visual training with targeted neuromodulation, offering a novel approach to visual rehabilitation in…
Foundation Fighting Blindness releases 4-year RUSH2A data to public | Ophthalmology Times
(Image Credit: AdobeStock/Ar_TH) Foundation Fighting Blindness has granted public access to de-identified 4-year data from individuals participating in RUSH2A, an ongoing natural history study for patients with mutations in the USH2A gene, which causes Usher syndrome type 2A or nonsyndromic retinitis pigmentosa…
Opus Genetics doses first patient in phase 1/2 clinical trial, BIRD-1, evaluating OPGx-BEST1 | Ophthalmology Times
(Image Credit: AdobeStock/Treecha) Opus Genetics has dosed the first patient in its OPGx-BEST1 phase 1/2 clinical trial, BIRD-1, for Best disease (BEST1). Best disease, also known as vitelliform macular dystrophy, is a rare, inherited retinal condition causing macular degeneration by…
Eradicating Demodex Blepharitis and Improving MGD with Lotilaner | Ophthalmology Times
The program begins with a discussion on the everyday challenges eye care professionals face in recognizing subtle signs of eyelid disease. The speaker explains how a structured clinical workflow—combining careful slit-lamp examination, patient history, and microscopic confirmation—can help practitioners avoid…
FDA accepts resubmitted ONS-5010 BLA from Outlook Therapeutics | Ophthalmology Times
(Image Credit: AdobeStock) The FDA has accepted for review a biologics license application (BLA) from Outlook Therapeutics for ONS-5010 (bevacizumab-vikg) for the treatment of wet age-related macular degeneration (wet AMD). ONS-5010 is a recombinant humanized monoclonal antibody (mAb) that selectively…
Apellis announces 5-year GALE study data in GA | Ophthalmology Times
Image credit: ©Proxima Studio/AdobeStock) Apellis Pharmaceuticals recently announced post hoc analysis data from the GALE extension study. The new data are the result of 5 years of continuous treatment with pegcetacoplan injection (Syfovre) in patients with geographic atrophy (GA) secondary…